<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04124328</url>
  </required_header>
  <id_info>
    <org_study_id>2515</org_study_id>
    <nct_id>NCT04124328</nct_id>
  </id_info>
  <brief_title>Evaluation of Vein of Marshall Ethanol Infusion During Left Atrial Linear Ablation in Patients With Persistent Atrial Fibrillation</brief_title>
  <acronym>MARSHALINE</acronym>
  <official_title>The MARSHALINE Study: Evaluation of Vein of Marshall Ethanol Infusion During Left Atrial Linear Ablation in Patients With Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AZ Sint-Jan AV</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective, randomized, controlled, unblinded, mono-center study, we aim to evaluate
      the efficacy of vein of Marshall ethanol infusion during left atrial linear ablation in
      patients with atrial fibrillation compared to the ALINE protocol.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural succes rate</measure>
    <time_frame>At time of ablation</time_frame>
    <description>Mitral isthmus block rate after one pass of the mitral line</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total procedure time</measure>
    <time_frame>At time of ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time</measure>
    <time_frame>At time of ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total RF ablation time</measure>
    <time_frame>At time of ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total extent of ablated LA tissue</measure>
    <time_frame>At time of ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular-related hospitalizations</measure>
    <time_frame>From time of ablation to one month post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life (SF36)</measure>
    <time_frame>From inclusion to one month post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of atrial flutter</measure>
    <time_frame>From time of ablation to one month post procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>ALINE only group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm are scheduled for an extended AF ablation, including the mitral isthmus line, according to the ALINE criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VoM group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm are scheduled for an extended AF ablation, including the mitral isthmus line, according to the ALINE criteria and vein of Marshall (VoM) ethanol infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ALINE + VoM infusion</intervention_name>
    <description>In patients assigned to the ALINE + VoM infusion group, extended ablation will be performed according to the ALINE criteria. Additionally, the vein of Marshall will be infused with ethanol.</description>
    <arm_group_label>VoM group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ALINE only</intervention_name>
    <description>In patients assigned to the ALINE only, extended ablation will be performed according to the ALINE criteria.</description>
    <arm_group_label>ALINE only group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between the ages of 18 and 85 years

          -  Diagnosed with symptomatic AF without previous mitral isthmus line ablation

        Exclusion Criteria:

          -  Previous MI line ablation

          -  Left atrial thrombus. LAA thrombus can be determined by preprocedural imaging: CT, TEE
             or MRI.

          -  LA diameter greater than 55 mm on long axis parasternal view, or left atrial volume
             more than 200 cc.

          -  Left ventricular ejection fraction &lt;35%.

          -  Cardiac surgery within the previous 90 days.

          -  Expecting cardiac transplantation or other cardiac surgery within 180 days.

          -  Coronary PTCA/stenting within the previous 90 days or myocardial infarction within the
             previous 60 days.

          -  Documented history of a thromboembolic event within the previous 90 days.

          -  Diagnosed atrial myxoma.

          -  Significant restrictive, constrictive, or chronic obstructive pulmonary disease with
             chronic symptoms.

          -  Significant congenital anomaly or medical problem that in the opinion of the
             investigator would preclude enrollment

          -  Women who are pregnant or who plan to become pregnant during the study.

          -  Acute illness or active infection at time of index procedure

          -  Renal insufficiency

          -  Unstable angina.

          -  History of blood clotting or bleeding abnormalities.

          -  Contraindication to anticoagulation.

          -  Life expectancy less than 1 year.

          -  Uncontrolled heart failure.

          -  Presence of a condition that precludes vascular access.

          -  INR greater than 3.5 within 24 hours of procedure - for patients taking warfarin.

          -  Patient cannot be removed from antiarrhythmic drugs for reasons other than AF.

          -  Unwilling or unable to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastien Knecht, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Sint-Jan Brugge Oostende AV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sebastien Knecht, MD, PhD</last_name>
    <phone>+32 50 45 26 70</phone>
    <email>sebastien.knecht@azsintjan.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle Lycke, MSc, PhD</last_name>
    <phone>+32 50 45 32 93</phone>
    <email>michelle.lycke@azsintjan.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge-Oostende AV</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SÃ©bastien Knecht, MD, PhD</last_name>
      <email>sebastien.knecht@azsintjan.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ Sint-Jan AV</investigator_affiliation>
    <investigator_full_name>Sebastien Knecht</investigator_full_name>
    <investigator_title>Professor Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

